The announcement of a class action lawsuit against Humacyte, Inc. is likely to negatively impact its stock price in the short term as investors may react to the potential legal and financial consequences. The lawsuit suggests possible issues with the company's compliance with federal securities laws, which could lead to financial penalties or settlements.